Home › Companies › Dianthus Therapeutics, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Dianthus Therapeutics, Inc.’s Form 8-K, filed May 22, 2026 (Item 5.07 on EDGAR). Page generated October 14, 2026.
Meeting of May 21, 2026: 5 items on Dianthus Therapeutics, Inc.’s Form 8-K, filed May 22, 2026: 2 approved · 3 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2024-2025 2025-2026
Explore Dianthus Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Dianthus Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 22, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Sujay Kango | 42,739,315 | -- | -- | 479,199 | 3,585,554 | 99% | Not verified | — |
| Elect Director: Anne McGeorge | 34,814,377 | -- | -- | 8,404,137 | 3,585,554 | 81% | Not verified | — |
| Elect Director: Jonathan Violin, Ph.D | 42,799,946 | -- | -- | 418,568 | 3,585,554 | 99.0% | Not verified | — |
| 2. Advisory Vote on Executive Compensation | 41,004,507 | 1,713,043 | 500,964 | -- | 3,585,554 | 96% | Approved | — |
| 3. Ratification of Appointment of Independent Registered Public Accounting Firm | 46,298,319 | 5,279 | 500,471 | -- | -- | 99.9% | Approved | — |
Source: Dianthus Therapeutics, Inc., Form 8-K, filed with the SEC on May 22, 2026 — read the filing on EDGAR.
Each item below shows how the 264 asset managers that disclosed a Dianthus Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 5 wordings of this item as funds reported it.
81% Majority: yes · of votes cast
Description as filed by funds: To elect Class II directors to our Board of Directors, to serve until the 2029 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal: Anne McGeorge
Dianthus Therapeutics, Inc.’s own tally for this item (“Elect Director: Anne McGeorge”): 34,814,377 for, 8,404,137 withheld, per its Form 8-K filed May 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 81% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 82 asset managers below reported 12,685,923 for, 3,384,356 withheld, 11 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,800,192 | 0 | 0 | 0 | For |
| Vanguard | 3,807,055 | 0 | 11 | 4,662 | For |
| T. Rowe Price | 828,892 | 0 | 0 | 854,698 | Mixed |
| BlackRock | 800,333 | 0 | 0 | 0 | For |
| ALGER INSTITUTIONAL FUNDS | 0 | 0 | 0 | 488,463 | Withhold |
| FRANKLIN STRATEGIC SERIES | 0 | 0 | 0 | 466,784 | Withhold |
| State Street | 423,123 | 0 | 0 | 1,134 | For |
| Charles Schwab | 305,883 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 0 | 0 | 288,417 | Withhold |
| ALGER FUNDS II | 0 | 0 | 0 | 230,381 | Withhold |
| MUTUAL FUND SERIES TRUST | 225,261 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 220,188 | 0 | 0 | 0 | For |
| Prudential/PGIM | 193,888 | 0 | 0 | 16,128 | Mixed |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 203,248 | Withhold |
| TIAA | 196,517 | 0 | 0 | 0 | For |
| Equitable | 89,332 | 0 | 0 | 99,924 | Mixed |
| ALGER FUNDS | 0 | 0 | 0 | 156,341 | Withhold |
| Dimensional | 0 | 0 | 0 | 110,894 | Withhold |
| Invesco | 90,139 | 0 | 0 | 0 | For |
| Hartford | 79,219 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 78,532 | Withhold |
| Lord Abbett | 71,635 | 0 | 0 | 0 | For |
| Principal | 0 | 0 | 0 | 65,125 | Withhold |
| Russell Investments | 63,644 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 58,266 | 0 | 0 | 0 | For |
Showing the 25 largest of 82 asset managers. See all 82 in the interactive database.
Combines 4 wordings of this item as funds reported it.
99.0% Majority: yes · of votes cast
Description as filed by funds: To elect Class II directors to our Board of Directors, to serve until the 2029 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal: Jonathan Violin, Ph.D.
Dianthus Therapeutics, Inc.’s own tally for this item (“Elect Director: Jonathan Violin, Ph.D”): 42,799,946 for, 418,568 withheld, per its Form 8-K filed May 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.0% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 82 asset managers below reported 15,934,925 for, 135,365 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,800,192 | 0 | 0 | 0 | For |
| Vanguard | 3,808,563 | 0 | 0 | 3,165 | For |
| T. Rowe Price | 1,683,590 | 0 | 0 | 0 | For |
| BlackRock | 800,333 | 0 | 0 | 0 | For |
| ALGER INSTITUTIONAL FUNDS | 488,463 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 466,784 | 0 | 0 | 0 | For |
| State Street | 423,649 | 0 | 0 | 608 | For |
| Charles Schwab | 305,883 | 0 | 0 | 0 | For |
| AllianceBernstein | 288,417 | 0 | 0 | 0 | For |
| ALGER FUNDS II | 230,381 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 225,261 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 220,188 | 0 | 0 | 0 | For |
| Prudential/PGIM | 209,682 | 0 | 0 | 334 | For |
| AB DISCOVERY GROWTH FUND, INC. | 203,248 | 0 | 0 | 0 | For |
| TIAA | 196,517 | 0 | 0 | 0 | For |
| Equitable | 189,256 | 0 | 0 | 0 | For |
| ALGER FUNDS | 156,341 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 110,894 | Withhold |
| Invesco | 90,139 | 0 | 0 | 0 | For |
| Hartford | 79,219 | 0 | 0 | 0 | For |
| American Century | 78,532 | 0 | 0 | 0 | For |
| Lord Abbett | 71,635 | 0 | 0 | 0 | For |
| Principal | 65,125 | 0 | 0 | 0 | For |
| Russell Investments | 63,644 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 58,266 | 0 | 0 | 0 | For |
Showing the 25 largest of 82 asset managers. See all 82 in the interactive database.
Combines 4 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: To elect Class II directors to our Board of Directors, to serve until the 2029 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal: Sujay Kango
Dianthus Therapeutics, Inc.’s own tally for this item (“Elect Director: Sujay Kango”): 42,739,315 for, 479,199 withheld, per its Form 8-K filed May 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 82 asset managers below reported 15,938,903 for, 131,386 withheld, 1 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,800,192 | 0 | 0 | 0 | For |
| Vanguard | 3,811,727 | 0 | 1 | 0 | For |
| T. Rowe Price | 1,683,590 | 0 | 0 | 0 | For |
| BlackRock | 800,333 | 0 | 0 | 0 | For |
| ALGER INSTITUTIONAL FUNDS | 488,463 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 466,784 | 0 | 0 | 0 | For |
| State Street | 424,257 | 0 | 0 | 0 | For |
| Charles Schwab | 305,883 | 0 | 0 | 0 | For |
| AllianceBernstein | 288,417 | 0 | 0 | 0 | For |
| ALGER FUNDS II | 230,381 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 225,261 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 220,188 | 0 | 0 | 0 | For |
| Prudential/PGIM | 209,682 | 0 | 0 | 334 | For |
| AB DISCOVERY GROWTH FUND, INC. | 203,248 | 0 | 0 | 0 | For |
| TIAA | 196,517 | 0 | 0 | 0 | For |
| Equitable | 189,256 | 0 | 0 | 0 | For |
| ALGER FUNDS | 156,341 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 110,894 | Withhold |
| Invesco | 90,139 | 0 | 0 | 0 | For |
| Hartford | 79,219 | 0 | 0 | 0 | For |
| American Century | 78,532 | 0 | 0 | 0 | For |
| Lord Abbett | 71,635 | 0 | 0 | 0 | For |
| Principal | 65,125 | 0 | 0 | 0 | For |
| Russell Investments | 63,644 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 58,266 | 0 | 0 | 0 | For |
Showing the 25 largest of 82 asset managers. See all 82 in the interactive database.
Combines 8 wordings of this item as funds reported it.
96% Approved · of votes cast
Description as filed by funds: To approve, on an advisory basis, the compensation paid to our named executive officers; and
Dianthus Therapeutics, Inc.’s own tally for this item (“2. Advisory Vote on Executive Compensation”): 41,004,507 for, 1,713,043 against — passed, per its Form 8-K filed May 22, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory basis, the compensation paid to the Company's named executive officers.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,800,192 | 0 | 0 | 0 | For |
| Vanguard | 3,811,725 | 3 | 1 | 0 | For |
| T. Rowe Price | 1,683,590 | 0 | 0 | 0 | For |
| BlackRock | 800,333 | 0 | 0 | 0 | For |
| ALGER INSTITUTIONAL FUNDS | 0 | 488,463 | 0 | 0 | Against |
| FRANKLIN STRATEGIC SERIES | 466,784 | 0 | 0 | 0 | For |
| State Street | 424,089 | 168 | 0 | 0 | For |
| Charles Schwab | 305,883 | 0 | 0 | 0 | For |
| AllianceBernstein | 288,417 | 0 | 0 | 0 | For |
| ALGER FUNDS II | 0 | 230,381 | 0 | 0 | Against |
| MUTUAL FUND SERIES TRUST | 225,261 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 220,188 | 0 | 0 | 0 | For |
| Prudential/PGIM | 210,016 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 203,248 | 0 | 0 | 0 | For |
| TIAA | 196,517 | 0 | 0 | 0 | For |
| Equitable | 189,256 | 0 | 0 | 0 | For |
| ALGER FUNDS | 0 | 156,341 | 0 | 0 | Against |
| Dimensional | 110,894 | 0 | 0 | 0 | For |
| Invesco | 0 | 90,139 | 0 | 0 | Against |
| Hartford | 79,219 | 0 | 0 | 0 | For |
| American Century | 0 | 78,532 | 0 | 0 | Against |
| Lord Abbett | 71,635 | 0 | 0 | 0 | For |
| Principal | 65,125 | 0 | 0 | 0 | For |
| Russell Investments | 63,644 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 58,266 | 0 | 0 | 0 | For |
Fund voting reports, all 82 managers: 14,966,247 for, 1,089,765 against, 14,279 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 6,285,483 | 0 | 0 | 0 | For |
| RA CAPITAL MANAGEMENT, L.P. | 2,611,733 | 0 | 0 | 0 | For |
| Fairmount Funds Management LLC | 2,537,191 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,282,295 | 0 | 0 | 0 | For |
| Wellington | 2,136,275 | 0 | 0 | 0 | For |
| Octagon Capital Advisors LP | 2,086,667 | 0 | 0 | 0 | For |
| Polar Capital Holdings Plc | 1,900,000 | 0 | 0 | 0 | For |
| BlackRock | 1,352,652 | 2,838 | 0 | 0 | For |
| Venrock Adviser, LLC | 1,180,000 | 0 | 0 | 0 | For |
| FRED ALGER MANAGEMENT, LLC | 55,873 | 1,097,202 | 0 | 0 | Against |
| FRANKLIN ADVISERS INC | 955,105 | 0 | 0 | 0 | For |
| AllianceBernstein | 889,829 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 736,590 | 0 | 0 | 0 | For |
| State Street | 493,523 | 1,095 | 0 | 0 | For |
| Catalio Capital Management, LP | 0 | 0 | 482,000 | 0 | Abstain |
| Logos Global Management LP | 475,000 | 0 | 0 | 0 | For |
| Citadel | 469,801 | 0 | 0 | 0 | For |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 456,711 | 0 | 0 | 0 | For |
| SILVERARC CAPITAL MANAGEMENT, LLC | 427,394 | 0 | 0 | 0 | For |
| BRAIDWELL LP | 404,325 | 0 | 0 | 0 | For |
| Cormorant Asset Management, LP | 393,151 | 0 | 0 | 0 | For |
| Bain Capital Life Sciences Investors, LLC | 362,470 | 0 | 0 | 0 | For |
| Vivo Capital, LLC | 353,998 | 0 | 0 | 0 | For |
| JENNISON ASSOCIATES LLC | 339,207 | 0 | 0 | 0 | For |
| Artisan | 332,171 | 0 | 0 | 0 | For |
Institutional-manager reports, all 203 managers: 34,526,519 for, 1,566,762 against, 497,652 abstained, 1,612 not voted. Showing the 25 largest; see all in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE, LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.
Dianthus Therapeutics, Inc.’s own tally for this item (“3. Ratification of Appointment of Independent Registered Public Accounting Firm”): 46,298,319 for, 5,279 against — passed, per its Form 8-K filed May 22, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Ratification of Appointment of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Deloitte & Touche, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 82 asset managers below reported 16,056,011 for, 14,279 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,800,192 | 0 | 0 | 0 | For |
| Vanguard | 3,811,727 | 0 | 1 | 0 | For |
| T. Rowe Price | 1,683,590 | 0 | 0 | 0 | For |
| BlackRock | 800,333 | 0 | 0 | 0 | For |
| ALGER INSTITUTIONAL FUNDS | 488,463 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 466,784 | 0 | 0 | 0 | For |
| State Street | 424,257 | 0 | 0 | 0 | For |
| Charles Schwab | 305,883 | 0 | 0 | 0 | For |
| AllianceBernstein | 288,417 | 0 | 0 | 0 | For |
| ALGER FUNDS II | 230,381 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 225,261 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 220,188 | 0 | 0 | 0 | For |
| Prudential/PGIM | 210,016 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 203,248 | 0 | 0 | 0 | For |
| TIAA | 196,517 | 0 | 0 | 0 | For |
| Equitable | 189,256 | 0 | 0 | 0 | For |
| ALGER FUNDS | 156,341 | 0 | 0 | 0 | For |
| Dimensional | 110,894 | 0 | 0 | 0 | For |
| Invesco | 90,139 | 0 | 0 | 0 | For |
| Hartford | 79,219 | 0 | 0 | 0 | For |
| American Century | 78,532 | 0 | 0 | 0 | For |
| Lord Abbett | 71,635 | 0 | 0 | 0 | For |
| Principal | 65,125 | 0 | 0 | 0 | For |
| Russell Investments | 63,644 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 58,266 | 0 | 0 | 0 | For |
Showing the 25 largest of 82 asset managers. See all 82 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 54,582,749 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 8.79% |
| 2 | Vanguard | 6.98% |
| 3 | T. Rowe Price | 3.08% |
| 4 | BlackRock | 1.47% |
| 5 | ALGER INSTITUTIONAL FUNDS | 0.89% |
| 6 | FRANKLIN STRATEGIC SERIES | 0.86% |
| 7 | State Street | 0.78% |
| 8 | Charles Schwab | 0.56% |
| 9 | AllianceBernstein | 0.53% |
| 10 | ALGER FUNDS II | 0.42% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 11.52% |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 4.78% |
| 3 | Fairmount Funds Management LLC | 4.65% |
| 4 | T. Rowe Price | 4.18% |
| 5 | Wellington | 3.91% |
| 6 | Octagon Capital Advisors LP | 3.82% |
| 7 | Polar Capital Holdings Plc | 3.48% |
| 8 | BlackRock | 2.48% |
| 9 | Venrock Adviser, LLC | 2.16% |
| 10 | FRED ALGER MANAGEMENT, LLC | 2.11% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| FMR (Fidelity) | 14.23% | 13F |
| BlackRock | 5.82% | 13F |
| RA Capital Management, L.P. | 4.78% | 13G |
| Wellington Management | 4.76% | 13F |
| Vanguard Group | 3.75% | 13F |
| Citadel Advisors | 3.02% | 13F |
| State Street | 2.56% | 13F |
| T. Rowe Price | 2.10% | 13F |
| Franklin Templeton | 1.77% | 13F |
| Geode Capital | 1.68% | 13F |
Percentages above are of 54,582,749 shares outstanding, as reported by Dianthus Therapeutics, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Dianthus Therapeutics, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.
At Dianthus Therapeutics, Inc.'s shareholder meeting held May 21, 2026, in the 2025-2026 proxy season, 264 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 1,670 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation paid to our named executive officers; and — Dianthus Therapeutics, Inc.'s filing reports the proposal as approved, with 96% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Dianthus Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 22, 2026.
Dianthus Therapeutics, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).
Download data (CSV): ballot items · votes by manager · column guide.